Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations

References

• Miller J, Wynn WH. Malignant tumor arising from endothelium of peritoneum, and producing mucoid ascitic fluid. J Pathol Bacteriol. 1908;12:267–278. doi:10.1002/path.1700120212
   Google Scholar
• Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14(1):41–49. doi:10.1245/s10434-006-9169-717039392
   PubMed Web of Science ®Google Scholar
• Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health. 2013;19(1):1–10. doi:10.1179/2049396712Y.000000001623582609
   PubMed Web of Science ®Google Scholar
• Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009;20(6):935–944. doi:10.1007/s10552-009-9328-919294523
   PubMed Web of Science ®Google Scholar
• Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997;145(3):211–218.9012593
   PubMed Web of Science ®Google Scholar
• Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39(7):576–588. doi:10.1080/1040844090304492819650718
   PubMed Web of Science ®Google Scholar
• Gilks B, Hegedus C, Freeman H, Fratkin L, Churg A. Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer. 1988;61(10):2019–2021.3282640
   PubMed Web of Science ®Google Scholar
• Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008;14(4):316–321. doi:10.1097/MCP.0b013e328301822018520265
   PubMed Web of Science ®Google Scholar
• Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7(2):147–154. doi:10.1038/nrc206817251920
   PubMed Web of Science ®Google Scholar
• Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007;9(2):32.
   PubMedGoogle Scholar
• Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18(6):985–990. doi:10.1093/annonc/mdl34517030547
   PubMed Web of Science ®Google Scholar
• Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17(6):525–534. doi:10.1097/CEJ.0b013e3282f0c0a218941374
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2009;99(1):51–57. doi:10.1002/jso.2116718942074
   PubMed Web of Science ®Google Scholar
• Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994;51(12):804–811.7849863
   PubMed Web of Science ®Google Scholar
• Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015;8(1):35–39. doi:10.1016/j.tranon.2014.12.00225749175
   PubMed Web of Science ®Google Scholar
• Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5(11):236. doi:10.21037/atm28706904
   PubMed Web of Science ®Google Scholar
• Alexander HR, Hanna N, Pingpank JF. Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma. Cancer Treat Res. 2007;134:343–355.17633065
   PubMedGoogle Scholar
• Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89(3):269–273.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12(3):605–621, xi.14567020
   PubMedGoogle Scholar
• Sethna K, Sugarbaker PH. Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation. Hepato-gastroenterology. 2005;52(64):1087–1089.16001635
   PubMedGoogle Scholar
• Esquivel J, Averbach A. Combined laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a patient with peritoneal mesothelioma. J Laparoendosc Adv Surg Tech A. 2009;19(4):505–507. doi:10.1089/lap.2008.039219405805
   PubMed Web of Science ®Google Scholar
• Kaya H, Sezgi C, Tanrikulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma. 2014;61(4):433–438. doi:10.4149/neo_2014_05324645844
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–6242. doi:10.1200/JCO.2009.23.964019917862
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Martinetti A, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14(8):2300–2308. doi:10.1245/s10434-007-9393-917510772
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Martinetti A, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14(2):500–508. doi:10.1245/s10434-006-9192-817151789
   PubMed Web of Science ®Google Scholar
• Busch JM, Kruskal JB, Wu B. Best cases from the AFIP. Malignant peritoneal mesothelioma. Radiographics. 2002;22(6):1511–1515. doi:10.1148/rg.22602512512432120
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol. 2008;191(3):814–825. doi:10.2214/AJR.07.362818716115
   PubMed Web of Science ®Google Scholar
• Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98(4):268–272. doi:10.1002/jso.2105518726890
   PubMed Web of Science ®Google Scholar
• Kebapci M, Vardareli E, Adapinar B, Acikalin M. CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol. 2003;13(12):2620–2626. doi:10.1007/s00330-003-1851-614634783
   PubMed Web of Science ®Google Scholar
• Ros PR, Yuschok TJ, Buck JL, Shekitka KM, Kaude JV. Peritoneal mesothelioma. Radiologic appearances correlated with histology. Acta Radiol. 1991;32(5):355–358.1910986
   PubMed Web of Science ®Google Scholar
• Levy AD, Arnaiz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics. 2008;28(2):583–607; quiz 621–582. doi:10.1148/rg.282075175
   PubMed Web of Science ®Google Scholar
• Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103(4):839–849. doi:10.1002/cncr.2083615637690
   PubMed Web of Science ®Google Scholar
• Patel NP, Taylor CA, Levine EA, Trupiano JK, Geisinger KR. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol. 2007;128(3):414–422. doi:10.1309/DV1JYBL8LLYYT4J517709315
   PubMed Web of Science ®Google Scholar
• Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology. 2001;39(6):584–588.11903576
   PubMed Web of Science ®Google Scholar
• Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the peritoneal surface oncology group international registry. Ann Surg Oncol. 2018;25(3):667–673. doi:10.1245/s10434-017-6293-5
   PubMed Web of Science ®Google Scholar
• Liu S, Staats P, Lee M, Alexander HR, Burke AP. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology. 2014;46(7):604–609. doi:10.1097/PAT.000000000000018125393250
   PubMed Web of Science ®Google Scholar
• Valente K, Blackham AU, Levine E, et al. A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype. Am J Surg Pathol. 2016;40(9):1243–1248. doi:10.1097/PAS.000000000000069627438989
   PubMed Web of Science ®Google Scholar
• Lee M, Alexander HR, Burke A. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy. Pathology. 2013;45(5):464–473. doi:10.1097/PAT.0b013e3283631cce23846294
   PubMed Web of Science ®Google Scholar
• Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591–1603. doi:10.1056/NEJMra05015216221782
   PubMed Web of Science ®Google Scholar
• Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647–667. doi:10.5858/arpa.2012-0214-OA22929121
   PubMed Web of Science ®Google Scholar
• AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2018.
   Google Scholar
• Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011;117(9):1855–1863. doi:10.1002/cncr.2564021509762
   PubMed Web of Science ®Google Scholar
• Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70(1):6–12.9989414
   PubMed Web of Science ®Google Scholar
• Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol. 1983;1(6):386–391. doi:10.1200/JCO.1983.1.6.3866668506
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644. doi:10.1200/JCO.2003.11.13612860938
   PubMed Web of Science ®Google Scholar
• Janne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40–46. doi:10.3816/CLC.2005.n.02016098243
   PubMed Web of Science ®Google Scholar
• Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011;32(1):102–110. doi:10.1055/s-0031-127287421500129
   PubMed Web of Science ®Google Scholar
• Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26(21):3567–3572. doi:10.1200/JCO.2007.15.286818640937
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414. doi:10.1016/S0140-6736(15)01238-626719230
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104–1111. doi:10.1016/S1470-2045(13)70381-424035405
   PubMed Web of Science ®Google Scholar
• Foster JM, Radhakrishna U, Govindarajan V, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol. 2010;8:88. doi:10.1186/1477-7819-8-8820942962
   PubMed Web of Science ®Google Scholar
• Govindan R, Kratzke RA, Herndon JE 2nd, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11(6):2300–2304. doi:10.1158/1078-0432.CCR-04-194015788680
   PubMed Web of Science ®Google Scholar
• Kanteti R, Dhanasingh I, Kawada I, et al. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014;9(9):e105919. doi:10.1371/journal.pone.010591925221930
   PubMed Web of Science ®Google Scholar
• Varghese S, Chen Z, Bartlett DL, et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011;117(2):361–371. doi:10.1002/cncr.2555520839315
   PubMed Web of Science ®Google Scholar
• Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol. 2018;25(7):2018–2026. doi:10.1245/s10434-018-6499-129721724
   PubMed Web of Science ®Google Scholar
• Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827–834. doi:10.1093/annonc/mdl42817130182
   PubMed Web of Science ®Google Scholar
• Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17(10):2720–2727. doi:10.1245/s10434-010-1080-620422458
   PubMed Web of Science ®Google Scholar
• Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–4567. doi:10.1200/JCO.2003.04.15014673042
   PubMed Web of Science ®Google Scholar
• Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13(3):405–412. doi:10.1245/ASO.2006.05.04116485159
   PubMed Web of Science ®Google Scholar
• Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229–237. doi:10.1245/ASO.2006.03.04516444562
   PubMed Web of Science ®Google Scholar
• Alexander HR Jr., Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779–786. doi:10.1016/j.surg.2013.01.00123489943
   PubMed Web of Science ®Google Scholar
• Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–1693. doi:10.1245/s10434-014-3978-x25124472
   PubMed Web of Science ®Google Scholar
• Levine EA, Stewart J, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573–585. doi:10.1016/j.jamcollsurg.2013.12.01324491244
   PubMed Web of Science ®Google Scholar
• Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA. Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(8):2152–2158. doi:10.1245/s10434-018-6336-629388121
   PubMed Web of Science ®Google Scholar
• Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3. doi:10.1186/1477-7800-2-315701175
   PubMedGoogle Scholar
• Malgras B, Gayat E, Aoun O, et al. Impact of combination chemotherapy in peritoneal mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): the RENAPE Study. Ann Surg Oncol. 2018;25(11):3271–3279. doi:10.1245/s10434-018-6631-229978366
   PubMed Web of Science ®Google Scholar
• Mazzocchi AR, Rajan SAP, Votanopoulos KI, Hall AR, Skardal A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018;8(1):2886. doi:10.1038/s41598-018-21200-829440675
   PubMedGoogle Scholar
• Facchiano E, Risio D, Kianmanesh R, Msika S. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol. 2012;19(9):2946–2950. doi:10.1245/s10434-012-2360-022526907
   PubMed Web of Science ®Google Scholar
• Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009;100(4):331–334. doi:10.1002/jso.2132119697441
   PubMed Web of Science ®Google Scholar
• Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1–9. doi:10.1007/s10147-012-0396-622460778
   PubMed Web of Science ®Google Scholar
• Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21(5):1474–1479. doi:10.1245/s10434-013-3224-y23982251
   PubMed Web of Science ®Google Scholar
• Le Roy F, Gelli M, Hollebecque A, et al. Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol. 2017;24(12):3640–3646. doi:10.1245/s10434-017-6033-x28849389
   PubMed Web of Science ®Google Scholar
• Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(11):2178–2183. doi:10.1016/j.ejso.2017.09.01028964609
   PubMed Web of Science ®Google Scholar
• Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21(4):1159–1165. doi:10.1245/s10434-013-3358-y24322529
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99(2):109–113. doi:10.1002/jso.2117719016259
   PubMed Web of Science ®Google Scholar
• Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013;20(2):555–561. doi:10.1245/s10434-012-2651-523233234
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17(1):45–53. doi:10.1245/s10434-009-0756-219856030
   PubMed Web of Science ®Google Scholar